Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis

Identifieur interne : 001244 ( Main/Exploration ); précédent : 001243; suivant : 001245

Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis

Auteurs : Duygu Emine Ersozlu Bozkirli [Turquie] ; Ilknur Kozanoglu [Turquie] ; Emre Bozkirli [Turquie] ; Eftal Yucel [Turquie]

Source :

RBID : ISTEX:44FA52A40BD9ADECE36F45A0A5514D64CF6D4ECA

Descripteurs français

English descriptors

Abstract

Antisynthetase syndrome (ASS) is characterized by inflammatory muscle disease, pulmonary and joint involvement, and antisynthetase autoantibodies, with anti‐Jo‐1 antibody being the most common. Despite the use of immunosuppressive drugs, the prognosis of lung involvement seems poor. Herein, we report a case of refractory ASS, which maintained long‐term remission by double filtration plasmapheresis (DFPP) combined with immunosuppressive therapy. For a 65‐year‐old woman, who was diagnosed with ASS, immunosuppressive therapy was initiated and plasmapheresis (PP) was performed five times due to acute interstitial pulmonary disease and inflammatory myopathy. She remained in remission for eight months following PP. Increase in interstitial involvement was identified by lung tomography when the patient presented again with complaint of progressive increase in dyspnea and muscle pain. Although the immunosuppressive therapy was increased for the patient with elevated creatine phosphokinase (CPK) (2776 IU/mL), a rapid decrease in diffusion capacity of the lung for carbon monoxide (DLCO) was observed and the patient underwent PP. After four sessions of therapy, insufficient clinical and laboratory response was obtained (control CPK 1797 IU/mL) and because of that issue DFPP using a 2A filter was performed to the patient. There was a marked improvement in complaints of the patient, DLCO, and laboratory findings (control CPK 508 IU/mL) after three sessions of DFPP. The patient, who continued the immunosuppressive therapy after DFPP procedure, is being followed for 12 months in remission. Although our experience is limited with only one patient, DFPP seems promising as a treatment option for ASS with severe lung involvement. J. Clin. Apheresis, 28:422–425, 2013. © 2013 Wiley Periodicals, Inc.

Url:
DOI: 10.1002/jca.21285


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis</title>
<author>
<name sortKey="Bozkirli, Duygu Emine Ersozlu" sort="Bozkirli, Duygu Emine Ersozlu" uniqKey="Bozkirli D" first="Duygu Emine Ersozlu" last="Bozkirli">Duygu Emine Ersozlu Bozkirli</name>
</author>
<author>
<name sortKey="Kozanoglu, Ilknur" sort="Kozanoglu, Ilknur" uniqKey="Kozanoglu I" first="Ilknur" last="Kozanoglu">Ilknur Kozanoglu</name>
</author>
<author>
<name sortKey="Bozkirli, Emre" sort="Bozkirli, Emre" uniqKey="Bozkirli E" first="Emre" last="Bozkirli">Emre Bozkirli</name>
</author>
<author>
<name sortKey="Yucel, Eftal" sort="Yucel, Eftal" uniqKey="Yucel E" first="Eftal" last="Yucel">Eftal Yucel</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:44FA52A40BD9ADECE36F45A0A5514D64CF6D4ECA</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/jca.21285</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-JZ7SGLT4-8/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000599</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000599</idno>
<idno type="wicri:Area/Istex/Curation">000599</idno>
<idno type="wicri:Area/Istex/Checkpoint">000296</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000296</idno>
<idno type="wicri:doubleKey">0733-2459:2013:Bozkirli D:antisynthetase:syndrome:with</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:23908096</idno>
<idno type="wicri:Area/PubMed/Corpus">000331</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000331</idno>
<idno type="wicri:Area/PubMed/Curation">000331</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000331</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000337</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000337</idno>
<idno type="wicri:Area/Ncbi/Merge">000207</idno>
<idno type="wicri:Area/Ncbi/Curation">000207</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000207</idno>
<idno type="wicri:Area/Main/Merge">001245</idno>
<idno type="wicri:Area/Main/Curation">001244</idno>
<idno type="wicri:Area/Main/Exploration">001244</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis</title>
<author>
<name sortKey="Bozkirli, Duygu Emine Ersozlu" sort="Bozkirli, Duygu Emine Ersozlu" uniqKey="Bozkirli D" first="Duygu Emine Ersozlu" last="Bozkirli">Duygu Emine Ersozlu Bozkirli</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Rheumatology, Baskent University School of Medicine, Adana</wicri:regionArea>
<wicri:noRegion>Adana</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author>
<name sortKey="Kozanoglu, Ilknur" sort="Kozanoglu, Ilknur" uniqKey="Kozanoglu I" first="Ilknur" last="Kozanoglu">Ilknur Kozanoglu</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Physiology, Baskent University School of Medicine, Adana</wicri:regionArea>
<wicri:noRegion>Adana</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bozkirli, Emre" sort="Bozkirli, Emre" uniqKey="Bozkirli E" first="Emre" last="Bozkirli">Emre Bozkirli</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Endocrinology and Metabolism, Baskent University School of Medicine, Adana</wicri:regionArea>
<wicri:noRegion>Adana</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Yucel, Eftal" sort="Yucel, Eftal" uniqKey="Yucel E" first="Eftal" last="Yucel">Eftal Yucel</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Rheumatology, Baskent University School of Medicine, Adana</wicri:regionArea>
<wicri:noRegion>Adana</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Journal of Clinical Apheresis</title>
<title level="j" type="alt">JOURNAL OF CLINICAL APHERESIS</title>
<idno type="ISSN">0733-2459</idno>
<idno type="eISSN">1098-1101</idno>
<imprint>
<biblScope unit="vol">28</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="422">422</biblScope>
<biblScope unit="page" to="425">425</biblScope>
<biblScope unit="page-count">4</biblScope>
<date type="published" when="2013-12">2013-12</date>
</imprint>
<idno type="ISSN">0733-2459</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0733-2459</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Autoantibodies (immunology)</term>
<term>Azathioprine (therapeutic use)</term>
<term>Combined Modality Therapy</term>
<term>Creatine Kinase (blood)</term>
<term>Cyclophosphamide (therapeutic use)</term>
<term>Emergencies</term>
<term>Female</term>
<term>Humans</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Lung Diseases, Interstitial (drug therapy)</term>
<term>Lung Diseases, Interstitial (etiology)</term>
<term>Lung Diseases, Interstitial (therapy)</term>
<term>Methylprednisolone (therapeutic use)</term>
<term>Myositis (complications)</term>
<term>Myositis (drug therapy)</term>
<term>Myositis (therapy)</term>
<term>Plasma</term>
<term>Plasmapheresis (methods)</term>
<term>Pulmonary Diffusing Capacity</term>
<term>Remission Induction</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Association thérapeutique</term>
<term>Autoanticorps (immunologie)</term>
<term>Azathioprine (usage thérapeutique)</term>
<term>Capacité de diffusion pulmonaire</term>
<term>Creatine kinase (sang)</term>
<term>Cyclophosphamide (usage thérapeutique)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Induction de rémission</term>
<term>Myosite ()</term>
<term>Myosite (traitement médicamenteux)</term>
<term>Méthylprednisolone (usage thérapeutique)</term>
<term>Plasma sanguin</term>
<term>Plasmaphérèse ()</term>
<term>Pneumopathies interstitielles ()</term>
<term>Pneumopathies interstitielles (traitement médicamenteux)</term>
<term>Pneumopathies interstitielles (étiologie)</term>
<term>Sujet âgé</term>
<term>Urgences</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Creatine Kinase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Autoantibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Azathioprine</term>
<term>Cyclophosphamide</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Methylprednisolone</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Myositis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Lung Diseases, Interstitial</term>
<term>Myositis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Autoanticorps</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Plasmapheresis</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Creatine kinase</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Lung Diseases, Interstitial</term>
<term>Myositis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Myosite</term>
<term>Pneumopathies interstitielles</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Azathioprine</term>
<term>Cyclophosphamide</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Méthylprednisolone</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Pneumopathies interstitielles</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Adana</term>
<term>Aged</term>
<term>American society</term>
<term>Antisynthetase</term>
<term>Antisynthetase syndrome</term>
<term>Apheresis</term>
<term>Apheresis applications committee</term>
<term>Azathioprine</term>
<term>Baskent</term>
<term>Baskent university school</term>
<term>Beneficial effects</term>
<term>Blood volume</term>
<term>Carbon monoxide</term>
<term>Clin</term>
<term>Clinical apheresis</term>
<term>Clinical course</term>
<term>Combined Modality Therapy</term>
<term>Cyclophosphamide</term>
<term>Dfpp</term>
<term>Dfpp therapy</term>
<term>Diffusion capacity</term>
<term>Dlco</term>
<term>Double filtration plasmapheresis</term>
<term>Dyspnea</term>
<term>Early diagnosis</term>
<term>Emergencies</term>
<term>Female</term>
<term>Filtration</term>
<term>First case</term>
<term>Flow rate volume</term>
<term>Hrct</term>
<term>Humans</term>
<term>Hydroxychloroquine</term>
<term>Immune complexes</term>
<term>Immunoglobulin</term>
<term>Immunosuppressive</term>
<term>Immunosuppressive therapy</term>
<term>Immunosuppressive treatment</term>
<term>Inflammatory</term>
<term>Inflammatory muscle disease</term>
<term>Interstitial</term>
<term>Interstitial involvement</term>
<term>Interstitial lung disease</term>
<term>Interstitial lung involvement</term>
<term>Intravenous</term>
<term>Muscle pain</term>
<term>Plasma</term>
<term>Plasma volume</term>
<term>Plasmapheresis</term>
<term>Pulmonary Diffusing Capacity</term>
<term>Pulmonary involvement</term>
<term>Remission</term>
<term>Remission Induction</term>
<term>Second activation</term>
<term>Session time</term>
<term>Syndrome</term>
<term>Therapeutic apheresis</term>
<term>Total blood volume</term>
<term>Wiley periodicals</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Association thérapeutique</term>
<term>Capacité de diffusion pulmonaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Induction de rémission</term>
<term>Myosite</term>
<term>Plasma sanguin</term>
<term>Plasmaphérèse</term>
<term>Pneumopathies interstitielles</term>
<term>Sujet âgé</term>
<term>Urgences</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Antisynthetase syndrome (ASS) is characterized by inflammatory muscle disease, pulmonary and joint involvement, and antisynthetase autoantibodies, with anti‐Jo‐1 antibody being the most common. Despite the use of immunosuppressive drugs, the prognosis of lung involvement seems poor. Herein, we report a case of refractory ASS, which maintained long‐term remission by double filtration plasmapheresis (DFPP) combined with immunosuppressive therapy. For a 65‐year‐old woman, who was diagnosed with ASS, immunosuppressive therapy was initiated and plasmapheresis (PP) was performed five times due to acute interstitial pulmonary disease and inflammatory myopathy. She remained in remission for eight months following PP. Increase in interstitial involvement was identified by lung tomography when the patient presented again with complaint of progressive increase in dyspnea and muscle pain. Although the immunosuppressive therapy was increased for the patient with elevated creatine phosphokinase (CPK) (2776 IU/mL), a rapid decrease in diffusion capacity of the lung for carbon monoxide (DLCO) was observed and the patient underwent PP. After four sessions of therapy, insufficient clinical and laboratory response was obtained (control CPK 1797 IU/mL) and because of that issue DFPP using a 2A filter was performed to the patient. There was a marked improvement in complaints of the patient, DLCO, and laboratory findings (control CPK 508 IU/mL) after three sessions of DFPP. The patient, who continued the immunosuppressive therapy after DFPP procedure, is being followed for 12 months in remission. Although our experience is limited with only one patient, DFPP seems promising as a treatment option for ASS with severe lung involvement. J. Clin. Apheresis, 28:422–425, 2013. © 2013 Wiley Periodicals, Inc.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Turquie</li>
</country>
</list>
<tree>
<country name="Turquie">
<noRegion>
<name sortKey="Bozkirli, Duygu Emine Ersozlu" sort="Bozkirli, Duygu Emine Ersozlu" uniqKey="Bozkirli D" first="Duygu Emine Ersozlu" last="Bozkirli">Duygu Emine Ersozlu Bozkirli</name>
</noRegion>
<name sortKey="Bozkirli, Emre" sort="Bozkirli, Emre" uniqKey="Bozkirli E" first="Emre" last="Bozkirli">Emre Bozkirli</name>
<name sortKey="Kozanoglu, Ilknur" sort="Kozanoglu, Ilknur" uniqKey="Kozanoglu I" first="Ilknur" last="Kozanoglu">Ilknur Kozanoglu</name>
<name sortKey="Yucel, Eftal" sort="Yucel, Eftal" uniqKey="Yucel E" first="Eftal" last="Yucel">Eftal Yucel</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001244 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001244 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:44FA52A40BD9ADECE36F45A0A5514D64CF6D4ECA
   |texte=   Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021